 Mary Hayden
Concepts (419)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cross Infection | 44 | 2021 | 291 | 8.390 |
Why?
| | beta-Lactamases | 26 | 2021 | 76 | 5.140 |
Why?
| | Klebsiella pneumoniae | 18 | 2021 | 61 | 4.630 |
Why?
| | Bacterial Proteins | 25 | 2021 | 93 | 4.160 |
Why?
| | Infection Control | 25 | 2021 | 168 | 3.740 |
Why?
| | Klebsiella Infections | 17 | 2020 | 56 | 3.490 |
Why?
| | Enterobacteriaceae Infections | 12 | 2021 | 48 | 3.470 |
Why?
| | Anti-Bacterial Agents | 36 | 2022 | 403 | 3.400 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 19 | 2021 | 107 | 3.380 |
Why?
| | Chlorhexidine | 17 | 2021 | 55 | 3.360 |
Why?
| | Gram-Positive Bacterial Infections | 20 | 2014 | 63 | 3.000 |
Why?
| | Vancomycin Resistance | 12 | 2014 | 31 | 2.910 |
Why?
| | Enterococcus | 21 | 2014 | 62 | 2.650 |
Why?
| | Anti-Infective Agents, Local | 11 | 2021 | 50 | 2.570 |
Why?
| | Enterobacteriaceae | 8 | 2020 | 39 | 2.530 |
Why?
| | Staphylococcal Infections | 20 | 2021 | 172 | 2.370 |
Why?
| | Disease Outbreaks | 15 | 2021 | 89 | 2.240 |
Why?
| | Bacteremia | 19 | 2019 | 122 | 2.240 |
Why?
| | Carrier State | 17 | 2019 | 52 | 2.190 |
Why?
| | Skin | 12 | 2021 | 144 | 1.960 |
Why?
| | Intensive Care Units | 24 | 2021 | 300 | 1.880 |
Why?
| | Baths | 9 | 2021 | 27 | 1.880 |
Why?
| | Drug Resistance, Multiple, Bacterial | 12 | 2020 | 49 | 1.800 |
Why?
| | Enterococcus faecium | 7 | 2020 | 16 | 1.710 |
Why?
| | Humans | 127 | 2022 | 30741 | 1.580 |
Why?
| | Drug Resistance, Bacterial | 10 | 2022 | 54 | 1.490 |
Why?
| | Housekeeping, Hospital | 3 | 2014 | 5 | 1.260 |
Why?
| | Carbapenems | 7 | 2019 | 32 | 1.250 |
Why?
| | Long-Term Care | 8 | 2019 | 57 | 1.240 |
Why?
| | Escherichia coli | 4 | 2018 | 67 | 1.230 |
Why?
| | Vancomycin | 14 | 2020 | 54 | 1.230 |
Why?
| | Candida | 3 | 2021 | 16 | 1.180 |
Why?
| | Microbial Sensitivity Tests | 21 | 2021 | 113 | 1.150 |
Why?
| | Mupirocin | 6 | 2019 | 15 | 1.100 |
Why?
| | Candidiasis | 2 | 2021 | 18 | 1.070 |
Why?
| | beta-Lactam Resistance | 4 | 2015 | 16 | 1.040 |
Why?
| | Clinical Laboratory Techniques | 2 | 2020 | 39 | 1.040 |
Why?
| | Skin Care | 4 | 2018 | 16 | 1.030 |
Why?
| | Population Surveillance | 7 | 2018 | 129 | 1.020 |
Why?
| | Hospital Administration | 3 | 2021 | 25 | 1.000 |
Why?
| | Chicago | 27 | 2021 | 945 | 1.000 |
Why?
| | Dermatomycoses | 1 | 2021 | 4 | 0.920 |
Why?
| | Disinfection | 4 | 2019 | 13 | 0.920 |
Why?
| | Coronavirus Infections | 2 | 2020 | 97 | 0.900 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 104 | 0.900 |
Why?
| | Hospitals | 14 | 2020 | 131 | 0.870 |
Why?
| | Clinical Protocols | 1 | 2021 | 74 | 0.870 |
Why?
| | Middle Aged | 49 | 2021 | 11256 | 0.860 |
Why?
| | Female | 60 | 2021 | 18107 | 0.860 |
Why?
| | Bacteriological Techniques | 3 | 2017 | 20 | 0.850 |
Why?
| | Culture Media | 5 | 2017 | 41 | 0.850 |
Why?
| | Male | 57 | 2021 | 17552 | 0.820 |
Why?
| | Catheterization, Central Venous | 2 | 2010 | 44 | 0.800 |
Why?
| | beta-Lactams | 2 | 2010 | 10 | 0.780 |
Why?
| | Mass Screening | 5 | 2018 | 199 | 0.780 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 13 | 2014 | 39 | 0.770 |
Why?
| | Infectious Disease Transmission, Professional-to-Patient | 3 | 2010 | 6 | 0.770 |
Why?
| | Genome, Bacterial | 3 | 2017 | 13 | 0.770 |
Why?
| | Community-Acquired Infections | 9 | 2020 | 75 | 0.750 |
Why?
| | Dengue | 3 | 2016 | 3 | 0.740 |
Why?
| | Equipment Contamination | 4 | 2019 | 28 | 0.730 |
Why?
| | Escherichia coli Infections | 5 | 2018 | 32 | 0.710 |
Why?
| | Aged | 36 | 2020 | 10156 | 0.710 |
Why?
| | Sensitivity and Specificity | 8 | 2020 | 594 | 0.640 |
Why?
| | Dengue Virus | 1 | 2015 | 1 | 0.610 |
Why?
| | Specimen Handling | 4 | 2020 | 51 | 0.600 |
Why?
| | Gram-Positive Bacteria | 2 | 2012 | 17 | 0.600 |
Why?
| | Health Personnel | 6 | 2021 | 97 | 0.580 |
Why?
| | Genomics | 5 | 2021 | 42 | 0.580 |
Why?
| | Virulence Factors | 1 | 2014 | 11 | 0.580 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2014 | 9 | 0.580 |
Why?
| | Skilled Nursing Facilities | 4 | 2020 | 16 | 0.580 |
Why?
| | Adult | 34 | 2021 | 9760 | 0.570 |
Why?
| | Bacterial Toxins | 1 | 2014 | 22 | 0.570 |
Why?
| | Nursing Homes | 5 | 2021 | 42 | 0.560 |
Why?
| | Bacterial Load | 3 | 2013 | 13 | 0.560 |
Why?
| | Hand | 5 | 2008 | 48 | 0.560 |
Why?
| | Gloves, Protective | 4 | 2019 | 15 | 0.550 |
Why?
| | Acinetobacter baumannii | 1 | 2014 | 5 | 0.550 |
Why?
| | Acinetobacter Infections | 1 | 2014 | 6 | 0.550 |
Why?
| | Anal Canal | 1 | 2014 | 14 | 0.550 |
Why?
| | Drug Resistance, Microbial | 13 | 1999 | 96 | 0.550 |
Why?
| | Methicillin Resistance | 4 | 2007 | 33 | 0.520 |
Why?
| | Disease Transmission, Infectious | 4 | 2021 | 22 | 0.490 |
Why?
| | Staphylococcus aureus | 4 | 2019 | 83 | 0.470 |
Why?
| | Prevalence | 12 | 2020 | 546 | 0.470 |
Why?
| | Critical Care | 3 | 2018 | 229 | 0.460 |
Why?
| | Gram-Negative Bacterial Infections | 3 | 2008 | 26 | 0.450 |
Why?
| | Rectum | 8 | 2018 | 69 | 0.440 |
Why?
| | DNA, Bacterial | 8 | 2019 | 56 | 0.430 |
Why?
| | Pandemics | 3 | 2020 | 157 | 0.420 |
Why?
| | Risk Factors | 15 | 2021 | 2611 | 0.410 |
Why?
| | United States | 12 | 2022 | 2467 | 0.410 |
Why?
| | Time Factors | 8 | 2020 | 1911 | 0.410 |
Why?
| | Polymerase Chain Reaction | 6 | 2020 | 209 | 0.400 |
Why?
| | Fomites | 1 | 2008 | 4 | 0.390 |
Why?
| | Delivery of Health Care | 2 | 2021 | 115 | 0.390 |
Why?
| | Decontamination | 1 | 2008 | 10 | 0.390 |
Why?
| | Urinary Tract Infections | 2 | 2022 | 33 | 0.390 |
Why?
| | Models, Theoretical | 2 | 2021 | 109 | 0.380 |
Why?
| | Hand Disinfection | 5 | 2019 | 24 | 0.380 |
Why?
| | Aedes | 3 | 2017 | 3 | 0.370 |
Why?
| | Disinfectants | 3 | 2014 | 9 | 0.370 |
Why?
| | Minisatellite Repeats | 1 | 2008 | 8 | 0.370 |
Why?
| | Endemic Diseases | 1 | 2008 | 7 | 0.370 |
Why?
| | Aged, 80 and over | 14 | 2018 | 5172 | 0.340 |
Why?
| | Genes, Bacterial | 2 | 2016 | 8 | 0.340 |
Why?
| | Bacteria | 2 | 2017 | 69 | 0.340 |
Why?
| | Sequence Analysis, DNA | 4 | 2017 | 97 | 0.330 |
Why?
| | Gram-Negative Bacteria | 4 | 2013 | 37 | 0.330 |
Why?
| | Serratia marcescens | 3 | 2011 | 11 | 0.330 |
Why?
| | Serratia Infections | 3 | 2011 | 10 | 0.330 |
Why?
| | Case-Control Studies | 8 | 2021 | 694 | 0.320 |
Why?
| | Illinois | 8 | 2021 | 268 | 0.310 |
Why?
| | Molecular Epidemiology | 7 | 2021 | 27 | 0.310 |
Why?
| | Daptomycin | 1 | 2005 | 17 | 0.310 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 389 | 0.300 |
Why?
| | Nasal Cavity | 5 | 2014 | 36 | 0.270 |
Why?
| | Drug Resistance, Multiple | 2 | 2012 | 12 | 0.270 |
Why?
| | Vancomycin-Resistant Enterococci | 2 | 2020 | 5 | 0.270 |
Why?
| | Drug Therapy, Combination | 2 | 1994 | 266 | 0.270 |
Why?
| | Pseudomonas aeruginosa | 2 | 2018 | 89 | 0.260 |
Why?
| | Environment | 2 | 2017 | 55 | 0.260 |
Why?
| | Models, Statistical | 2 | 2015 | 146 | 0.260 |
Why?
| | Plasmids | 3 | 2019 | 53 | 0.250 |
Why?
| | Protective Clothing | 2 | 2019 | 10 | 0.240 |
Why?
| | Respiratory Tract Infections | 2 | 2020 | 53 | 0.240 |
Why?
| | Subacute Care | 1 | 2021 | 5 | 0.240 |
Why?
| | Universities | 1 | 2021 | 29 | 0.230 |
Why?
| | Students | 1 | 2021 | 39 | 0.220 |
Why?
| | Mandatory Programs | 1 | 2021 | 2 | 0.220 |
Why?
| | Masks | 1 | 2021 | 4 | 0.220 |
Why?
| | State Government | 1 | 2021 | 7 | 0.220 |
Why?
| | Disease Reservoirs | 3 | 2010 | 10 | 0.220 |
Why?
| | Local Government | 1 | 2021 | 6 | 0.220 |
Why?
| | Federal Government | 1 | 2021 | 6 | 0.220 |
Why?
| | Gammaproteobacteria | 1 | 2021 | 3 | 0.220 |
Why?
| | Occupational Exposure | 1 | 2021 | 27 | 0.220 |
Why?
| | Viruses | 1 | 2020 | 9 | 0.220 |
Why?
| | Florida | 3 | 2016 | 17 | 0.220 |
Why?
| | Drug Contamination | 2 | 2011 | 7 | 0.220 |
Why?
| | Universal Precautions | 1 | 2020 | 3 | 0.220 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2020 | 13 | 0.220 |
Why?
| | Nasopharynx | 1 | 2020 | 13 | 0.220 |
Why?
| | Radiology, Interventional | 1 | 2020 | 8 | 0.210 |
Why?
| | Prisons | 2 | 2013 | 13 | 0.210 |
Why?
| | Communicable Diseases | 1 | 2020 | 15 | 0.210 |
Why?
| | Bacterial Infections | 1 | 2021 | 71 | 0.210 |
Why?
| | Fresh Water | 1 | 2020 | 5 | 0.210 |
Why?
| | Sepsis | 2 | 2014 | 155 | 0.210 |
Why?
| | Survivors | 1 | 2020 | 64 | 0.210 |
Why?
| | Adolescent | 11 | 2021 | 2627 | 0.210 |
Why?
| | Water Microbiology | 2 | 2020 | 12 | 0.200 |
Why?
| | Computer Simulation | 1 | 2021 | 246 | 0.200 |
Why?
| | Treatment Outcome | 9 | 2018 | 3850 | 0.200 |
Why?
| | Fluoroquinolones | 1 | 2019 | 24 | 0.200 |
Why?
| | Critical Illness | 3 | 2018 | 120 | 0.200 |
Why?
| | Medical Errors | 1 | 2019 | 31 | 0.190 |
Why?
| | Loiasis | 1 | 1998 | 3 | 0.190 |
Why?
| | Eye Infections, Parasitic | 1 | 1998 | 4 | 0.190 |
Why?
| | West Nile Fever | 2 | 2016 | 5 | 0.190 |
Why?
| | Environmental Microbiology | 2 | 2017 | 4 | 0.190 |
Why?
| | Temperature | 2 | 2017 | 84 | 0.190 |
Why?
| | Molecular Diagnostic Techniques | 2 | 2020 | 15 | 0.190 |
Why?
| | Disease Notification | 1 | 2018 | 4 | 0.190 |
Why?
| | Comorbidity | 2 | 2019 | 562 | 0.190 |
Why?
| | Conjugation, Genetic | 2 | 1997 | 5 | 0.180 |
Why?
| | Child | 7 | 2021 | 1547 | 0.180 |
Why?
| | Animals | 8 | 2020 | 5221 | 0.180 |
Why?
| | Infant | 5 | 2021 | 660 | 0.180 |
Why?
| | Bacterial Typing Techniques | 4 | 2011 | 12 | 0.180 |
Why?
| | Personnel, Hospital | 2 | 2008 | 19 | 0.170 |
Why?
| | Glycopeptides | 1 | 1997 | 3 | 0.170 |
Why?
| | Thailand | 2 | 2014 | 14 | 0.170 |
Why?
| | Teicoplanin | 2 | 1994 | 5 | 0.170 |
Why?
| | Ciprofloxacin | 3 | 2008 | 28 | 0.170 |
Why?
| | Feces | 1 | 2017 | 82 | 0.170 |
Why?
| | Hospitalization | 4 | 2019 | 344 | 0.170 |
Why?
| | Selection, Genetic | 1 | 2016 | 6 | 0.170 |
Why?
| | Chromogenic Compounds | 2 | 2013 | 3 | 0.160 |
Why?
| | Multilocus Sequence Typing | 4 | 2021 | 12 | 0.160 |
Why?
| | Young Adult | 6 | 2021 | 2249 | 0.160 |
Why?
| | Mosquito Control | 1 | 2016 | 1 | 0.160 |
Why?
| | Financing, Government | 1 | 2016 | 14 | 0.160 |
Why?
| | Models, Biological | 2 | 2014 | 428 | 0.160 |
Why?
| | Melioidosis | 1 | 2015 | 3 | 0.160 |
Why?
| | Burkholderia pseudomallei | 1 | 2015 | 3 | 0.160 |
Why?
| | Travel | 1 | 2015 | 15 | 0.150 |
Why?
| | Infant, Newborn | 5 | 2021 | 751 | 0.150 |
Why?
| | Ofloxacin | 1 | 1995 | 5 | 0.150 |
Why?
| | Levofloxacin | 1 | 1995 | 5 | 0.150 |
Why?
| | Markov Chains | 1 | 2015 | 32 | 0.150 |
Why?
| | Rain | 1 | 2015 | 1 | 0.150 |
Why?
| | West Nile virus | 1 | 2015 | 2 | 0.150 |
Why?
| | Monte Carlo Method | 1 | 2015 | 56 | 0.150 |
Why?
| | Nontuberculous Mycobacteria | 1 | 2015 | 5 | 0.150 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2015 | 9 | 0.150 |
Why?
| | Soaps | 3 | 2010 | 9 | 0.150 |
Why?
| | Biomedical Research | 1 | 2016 | 85 | 0.150 |
Why?
| | Hospitals, University | 1 | 2015 | 45 | 0.150 |
Why?
| | Data Collection | 1 | 2015 | 118 | 0.140 |
Why?
| | Cost Savings | 1 | 2014 | 39 | 0.140 |
Why?
| | Patient Care | 2 | 2013 | 34 | 0.140 |
Why?
| | Pharynx | 1 | 2014 | 14 | 0.140 |
Why?
| | Tertiary Care Centers | 3 | 2019 | 83 | 0.140 |
Why?
| | Child, Preschool | 4 | 2021 | 803 | 0.140 |
Why?
| | Medical Staff, Hospital | 1 | 2014 | 20 | 0.140 |
Why?
| | Mandatory Reporting | 1 | 2013 | 5 | 0.140 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2013 | 5 | 0.130 |
Why?
| | Colorimetry | 1 | 2013 | 2 | 0.130 |
Why?
| | Phylogeny | 3 | 2021 | 81 | 0.130 |
Why?
| | Air Microbiology | 1 | 2013 | 3 | 0.130 |
Why?
| | Multivariate Analysis | 4 | 2013 | 391 | 0.130 |
Why?
| | Fungi | 1 | 2013 | 6 | 0.130 |
Why?
| | Poisson Distribution | 2 | 2010 | 26 | 0.130 |
Why?
| | Aerosols | 1 | 2013 | 22 | 0.130 |
Why?
| | Prospective Studies | 6 | 2019 | 1891 | 0.120 |
Why?
| | Catheter-Related Infections | 1 | 2012 | 25 | 0.120 |
Why?
| | Attitude of Health Personnel | 1 | 2014 | 179 | 0.120 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 63 | 0.120 |
Why?
| | Epidemiologic Methods | 1 | 2012 | 23 | 0.120 |
Why?
| | Cohort Studies | 2 | 2012 | 1959 | 0.120 |
Why?
| | Quality of Health Care | 1 | 2013 | 135 | 0.120 |
Why?
| | Patient Transfer | 1 | 2012 | 24 | 0.120 |
Why?
| | Hospitals, Teaching | 4 | 2010 | 37 | 0.110 |
Why?
| | Cluster Analysis | 3 | 2018 | 56 | 0.110 |
Why?
| | Staphylococcal Skin Infections | 2 | 2007 | 14 | 0.110 |
Why?
| | Ecosystem | 2 | 2021 | 23 | 0.110 |
Why?
| | Enterococcus faecalis | 2 | 2002 | 8 | 0.110 |
Why?
| | Soft Tissue Infections | 2 | 2007 | 25 | 0.110 |
Why?
| | Blood | 1 | 2009 | 28 | 0.100 |
Why?
| | Retrospective Studies | 3 | 2021 | 3456 | 0.100 |
Why?
| | Administration, Intranasal | 2 | 2019 | 26 | 0.100 |
Why?
| | Severe Dengue | 1 | 2008 | 1 | 0.090 |
Why?
| | Imipenem | 1 | 2008 | 7 | 0.090 |
Why?
| | Academic Medical Centers | 1 | 2009 | 162 | 0.090 |
Why?
| | Pseudomonas Infections | 1 | 2008 | 60 | 0.090 |
Why?
| | Public Housing | 1 | 2007 | 5 | 0.090 |
Why?
| | Catheterization | 1 | 2007 | 64 | 0.090 |
Why?
| | Indicators and Reagents | 1 | 2007 | 19 | 0.090 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2007 | 20 | 0.090 |
Why?
| | Public Health | 2 | 2019 | 63 | 0.080 |
Why?
| | Simplexvirus | 1 | 2006 | 11 | 0.080 |
Why?
| | Hepatitis | 1 | 2006 | 9 | 0.080 |
Why?
| | DNA, Viral | 1 | 2007 | 117 | 0.080 |
Why?
| | Syringes | 3 | 2011 | 12 | 0.080 |
Why?
| | Bone Marrow Transplantation | 1 | 2006 | 44 | 0.080 |
Why?
| | Cytomegalovirus | 1 | 2007 | 83 | 0.080 |
Why?
| | Colony Count, Microbial | 3 | 2015 | 24 | 0.080 |
Why?
| | Viral Load | 1 | 2007 | 211 | 0.080 |
Why?
| | Guideline Adherence | 1 | 2007 | 81 | 0.080 |
Why?
| | Seroepidemiologic Studies | 2 | 2021 | 24 | 0.080 |
Why?
| | Program Evaluation | 1 | 2007 | 152 | 0.080 |
Why?
| | Geography | 2 | 2017 | 21 | 0.080 |
Why?
| | Culex | 2 | 2016 | 3 | 0.080 |
Why?
| | Osteomyelitis | 1 | 2005 | 22 | 0.080 |
Why?
| | HIV Infections | 1 | 2013 | 915 | 0.080 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 1997 | 47 | 0.080 |
Why?
| | Proportional Hazards Models | 3 | 2019 | 385 | 0.080 |
Why?
| | Ampicillin | 2 | 1995 | 8 | 0.070 |
Why?
| | Lumbosacral Region | 1 | 2005 | 65 | 0.070 |
Why?
| | Treatment Failure | 1 | 2005 | 188 | 0.070 |
Why?
| | Ascomycota | 1 | 2004 | 2 | 0.070 |
Why?
| | Mitosporic Fungi | 1 | 2004 | 2 | 0.070 |
Why?
| | Fungemia | 1 | 2004 | 6 | 0.070 |
Why?
| | Drug Synergism | 2 | 1994 | 68 | 0.070 |
Why?
| | Kidney Transplantation | 1 | 2006 | 144 | 0.070 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 2004 | 16 | 0.070 |
Why?
| | Mycoses | 1 | 2004 | 21 | 0.070 |
Why?
| | Aminoglycosides | 2 | 2013 | 12 | 0.070 |
Why?
| | Longitudinal Studies | 2 | 2019 | 1432 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2020 | 2046 | 0.070 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 957 | 0.070 |
Why?
| | Renal Dialysis | 1 | 2004 | 108 | 0.060 |
Why?
| | Membrane Transport Proteins | 2 | 2014 | 52 | 0.060 |
Why?
| | Hemolysin Proteins | 1 | 2002 | 2 | 0.060 |
Why?
| | Gelatinases | 1 | 2002 | 4 | 0.060 |
Why?
| | Mexico | 2 | 2015 | 18 | 0.060 |
Why?
| | Maryland | 1 | 2021 | 10 | 0.060 |
Why?
| | Georgia | 1 | 2021 | 16 | 0.060 |
Why?
| | Mathematics | 1 | 2000 | 36 | 0.060 |
Why?
| | Ventilators, Mechanical | 1 | 2020 | 19 | 0.060 |
Why?
| | Immunity, Humoral | 1 | 2020 | 8 | 0.050 |
Why?
| | Blood-Borne Pathogens | 1 | 2020 | 5 | 0.050 |
Why?
| | Heparin | 2 | 2011 | 38 | 0.050 |
Why?
| | Waste Disposal, Fluid | 1 | 2020 | 3 | 0.050 |
Why?
| | Homosexuality, Male | 1 | 2020 | 26 | 0.050 |
Why?
| | Immunity, Cellular | 1 | 2020 | 70 | 0.050 |
Why?
| | Cephalosporins | 2 | 1998 | 18 | 0.050 |
Why?
| | Escherichia coli Proteins | 1 | 2020 | 15 | 0.050 |
Why?
| | Sodium Chloride | 2 | 2011 | 44 | 0.050 |
Why?
| | California | 1 | 2019 | 34 | 0.050 |
Why?
| | Statistics as Topic | 2 | 2015 | 123 | 0.050 |
Why?
| | Lumbar Vertebrae | 1 | 2005 | 446 | 0.050 |
Why?
| | Confidence Intervals | 2 | 2012 | 105 | 0.050 |
Why?
| | Hygiene | 1 | 2019 | 13 | 0.050 |
Why?
| | Carbon-Oxygen Ligases | 1 | 1999 | 2 | 0.050 |
Why?
| | Residence Characteristics | 1 | 2021 | 222 | 0.050 |
Why?
| | Integrons | 1 | 2018 | 2 | 0.050 |
Why?
| | ROC Curve | 1 | 2019 | 155 | 0.050 |
Why?
| | Pilot Projects | 1 | 2020 | 440 | 0.050 |
Why?
| | Registries | 1 | 2020 | 203 | 0.050 |
Why?
| | Incidence | 2 | 2015 | 827 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2020 | 228 | 0.040 |
Why?
| | Surgical Wound Infection | 1 | 1999 | 102 | 0.040 |
Why?
| | Chromosomes, Bacterial | 1 | 1997 | 2 | 0.040 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 1997 | 11 | 0.040 |
Why?
| | Genotype | 1 | 1999 | 447 | 0.040 |
Why?
| | Patient Education as Topic | 1 | 2019 | 192 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 52 | 0.040 |
Why?
| | Ceftazidime | 1 | 1996 | 13 | 0.040 |
Why?
| | Gloves, Surgical | 1 | 1996 | 7 | 0.040 |
Why?
| | Gastrointestinal Tract | 1 | 2017 | 51 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2020 | 831 | 0.040 |
Why?
| | Arizona | 1 | 2016 | 4 | 0.040 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2016 | 77 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2017 | 369 | 0.040 |
Why?
| | Length of Stay | 2 | 2014 | 371 | 0.040 |
Why?
| | Bacteriuria | 1 | 2015 | 6 | 0.040 |
Why?
| | Costs and Cost Analysis | 1 | 2016 | 39 | 0.040 |
Why?
| | Borrelia burgdorferi Group | 1 | 1995 | 6 | 0.040 |
Why?
| | Ticks | 1 | 1995 | 5 | 0.040 |
Why?
| | Respiration, Artificial | 2 | 2012 | 111 | 0.040 |
Why?
| | Penicillins | 1 | 1995 | 13 | 0.040 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2015 | 14 | 0.040 |
Why?
| | Insect Vectors | 1 | 2015 | 2 | 0.040 |
Why?
| | Climate | 1 | 2015 | 4 | 0.040 |
Why?
| | Gastric Juice | 1 | 2015 | 3 | 0.040 |
Why?
| | Drinking Water | 1 | 2015 | 4 | 0.040 |
Why?
| | Sputum | 1 | 2015 | 23 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2015 | 19 | 0.040 |
Why?
| | Anti-Infective Agents | 1 | 1995 | 58 | 0.040 |
Why?
| | Seasons | 1 | 2015 | 45 | 0.040 |
Why?
| | Drugs, Investigational | 1 | 1994 | 12 | 0.040 |
Why?
| | Gentamicins | 1 | 1994 | 15 | 0.040 |
Why?
| | Genetic Markers | 1 | 2014 | 65 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2016 | 362 | 0.040 |
Why?
| | Organizational Culture | 1 | 2014 | 22 | 0.030 |
Why?
| | Campylobacter Infections | 1 | 2014 | 11 | 0.030 |
Why?
| | Diffusion | 1 | 2014 | 29 | 0.030 |
Why?
| | Species Specificity | 1 | 2014 | 77 | 0.030 |
Why?
| | Reimbursement, Incentive | 1 | 2013 | 6 | 0.030 |
Why?
| | Focus Groups | 1 | 2014 | 91 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2014 | 76 | 0.030 |
Why?
| | Longevity | 1 | 2014 | 34 | 0.030 |
Why?
| | Chickens | 1 | 2014 | 55 | 0.030 |
Why?
| | Colistin | 1 | 2013 | 4 | 0.030 |
Why?
| | Minocycline | 1 | 2013 | 8 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2013 | 8 | 0.030 |
Why?
| | Hospitals, Public | 2 | 2007 | 31 | 0.030 |
Why?
| | Hospital Costs | 1 | 2014 | 74 | 0.030 |
Why?
| | Communicable Disease Control | 1 | 2013 | 11 | 0.030 |
Why?
| | Sex Factors | 1 | 2015 | 535 | 0.030 |
Why?
| | Qualitative Research | 1 | 2014 | 118 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2013 | 9 | 0.030 |
Why?
| | Ventilation | 1 | 2013 | 4 | 0.030 |
Why?
| | Phenotype | 1 | 2014 | 368 | 0.030 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 217 | 0.030 |
Why?
| | Propensity Score | 1 | 2012 | 54 | 0.030 |
Why?
| | Agar | 1 | 2012 | 2 | 0.030 |
Why?
| | Nose | 1 | 2013 | 34 | 0.030 |
Why?
| | Contact Tracing | 1 | 2011 | 7 | 0.030 |
Why?
| | Indiana | 1 | 2011 | 17 | 0.030 |
Why?
| | Odds Ratio | 1 | 2012 | 328 | 0.030 |
Why?
| | Serratia | 1 | 2010 | 7 | 0.030 |
Why?
| | APACHE | 2 | 2001 | 33 | 0.030 |
Why?
| | Patient Isolation | 1 | 2010 | 24 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2010 | 148 | 0.030 |
Why?
| | Drug and Narcotic Control | 1 | 2009 | 8 | 0.030 |
Why?
| | Isotonic Solutions | 1 | 2009 | 17 | 0.030 |
Why?
| | Quality Control | 1 | 2009 | 48 | 0.030 |
Why?
| | Safety | 1 | 2009 | 57 | 0.030 |
Why?
| | Drug Industry | 1 | 2009 | 30 | 0.030 |
Why?
| | China | 1 | 2009 | 121 | 0.020 |
Why?
| | United States Food and Drug Administration | 1 | 2009 | 78 | 0.020 |
Why?
| | Texas | 1 | 2008 | 8 | 0.020 |
Why?
| | Bacterial Outer Membrane Proteins | 1 | 2008 | 10 | 0.020 |
Why?
| | Neural Tube Defects | 1 | 2008 | 10 | 0.020 |
Why?
| | Porins | 1 | 2008 | 23 | 0.020 |
Why?
| | Bedding and Linens | 1 | 2007 | 5 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2007 | 81 | 0.020 |
Why?
| | Blotting, Western | 1 | 2008 | 235 | 0.020 |
Why?
| | Methicillin | 1 | 2007 | 4 | 0.020 |
Why?
| | Gram-Positive Cocci | 1 | 2007 | 5 | 0.020 |
Why?
| | Alcohols | 1 | 2007 | 7 | 0.020 |
Why?
| | Environmental Monitoring | 1 | 2006 | 9 | 0.020 |
Why?
| | Cytomegalovirus Infections | 1 | 2007 | 84 | 0.020 |
Why?
| | Patients | 1 | 2006 | 26 | 0.020 |
Why?
| | Asphyxia Neonatorum | 1 | 1984 | 1 | 0.020 |
Why?
| | Animals, Newborn | 1 | 1984 | 77 | 0.020 |
Why?
| | Probability | 1 | 2004 | 107 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2007 | 875 | 0.020 |
Why?
| | Survival Analysis | 1 | 2004 | 398 | 0.020 |
Why?
| | Blood Glucose | 1 | 1984 | 136 | 0.020 |
Why?
| | Virulence | 1 | 2002 | 11 | 0.020 |
Why?
| | Drug Resistance | 1 | 2002 | 67 | 0.020 |
Why?
| | Mortality | 1 | 2002 | 97 | 0.010 |
Why?
| | Prognosis | 1 | 2004 | 1045 | 0.010 |
Why?
| | Risk Assessment | 1 | 2004 | 804 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2004 | 1233 | 0.010 |
Why?
| | Hospital Bed Capacity, 500 and over | 1 | 1998 | 9 | 0.010 |
Why?
| | Surgical Procedures, Operative | 1 | 1999 | 40 | 0.010 |
Why?
| | Enteral Nutrition | 1 | 1998 | 64 | 0.010 |
Why?
| | Risk | 1 | 1998 | 232 | 0.010 |
Why?
| | Genetic Variation | 1 | 1998 | 117 | 0.010 |
Why?
| | Digestive System | 1 | 1996 | 19 | 0.010 |
Why?
| | Sequence Analysis | 1 | 1995 | 4 | 0.010 |
Why?
| | Sequence Alignment | 1 | 1995 | 30 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1995 | 252 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1995 | 316 | 0.010 |
Why?
| | Pyruvates | 1 | 1984 | 3 | 0.000 |
Why?
| | Lactates | 1 | 1984 | 9 | 0.000 |
Why?
| | Rats, Inbred Strains | 1 | 1984 | 46 | 0.000 |
Why?
| | Glycogen | 1 | 1984 | 11 | 0.000 |
Why?
| | Catecholamines | 1 | 1984 | 18 | 0.000 |
Why?
| | Glucagon | 1 | 1984 | 6 | 0.000 |
Why?
| | Insulin | 1 | 1984 | 115 | 0.000 |
Why?
| | Liver | 1 | 1984 | 216 | 0.000 |
Why?
| | Rats | 1 | 1984 | 954 | 0.000 |
Why?
|
|
Hayden's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|